101 related articles for article (PubMed ID: 23802409)
1. The in vitro anti-tumor efficacy and the pharmacokinetics of N3-o-toluyl-fluorouracil loaded nanosuspension (TFu-LNS).
Li M; Zhang J; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2013 May; 9(5):801-10. PubMed ID: 23802409
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
Zhang J; Li M; Liu Z; Wang L; Liu Y; Zhang N
Int J Nanomedicine; 2014; 9():2741-51. PubMed ID: 24920908
[TBL] [Abstract][Full Text] [Related]
3. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Liu J; Li X; Cheng YN; Cui SX; Chen MH; Xu WF; Tian ZG; Makuuchi M; Tang W; Qu XJ
Eur J Pharmacol; 2007 Nov; 574(1):1-7. PubMed ID: 17904544
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
Sun W; Zhang N; Li A; Zou W; Xu W
Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.
Liu J; Xu WF; Cui SX; Zhou Y; Yuan YX; Chen MH; Wang RH; Gai RY; Makuuchi M; Tang W; Qu XJ
World J Gastroenterol; 2006 Nov; 12(42):6766-70. PubMed ID: 17106923
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration.
Sun W; Zou W; Huang G; Li A; Zhang N
J Drug Target; 2008 Jun; 16(5):357-65. PubMed ID: 18569280
[TBL] [Abstract][Full Text] [Related]
8. Release mechanism studies on TFu nanoparticles-in-microparticles system.
Sun W; Zhang N; Li X
Colloids Surf B Biointerfaces; 2012 Jun; 95():115-20. PubMed ID: 22424827
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
Ahmed F; Kumari S; Kondapi AK
Pharm Res; 2018 Jul; 35(9):178. PubMed ID: 30014319
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives.
Marchal JA; Boulaiz H; Suárez I; Saniger E; Campos J; Carrillo E; Prados J; Gallo MA; Espinosa A; Aránega A
Invest New Drugs; 2004 Nov; 22(4):379-89. PubMed ID: 15292708
[TBL] [Abstract][Full Text] [Related]
11. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
12. Methylglyoxal in combination with 5-Fluorouracil elicits improved chemosensitivity in breast cancer through apoptosis and cell cycle inhibition.
Ghosh S; Pal A; Ray M
Biomed Pharmacother; 2019 Jun; 114():108855. PubMed ID: 31003140
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery.
Liu C; Liu D; Bai F; Zhang J; Zhang N
Drug Deliv; 2010 Jul; 17(5):352-63. PubMed ID: 20387993
[TBL] [Abstract][Full Text] [Related]
14. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil.
Fujii H; Horie S; Sukhbaatar A; Mishra R; Sakamoto M; Mori S; Kodama T
Cancer Med; 2019 May; 8(5):2241-2251. PubMed ID: 30945479
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation.
Shibamoto Y; Zhou L; Hatta H; Mori M; Nishimoto SI
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):407-13. PubMed ID: 11173134
[TBL] [Abstract][Full Text] [Related]
17. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 5-fluorouracil aerosol on the growth of human gastric cancer cell line MKN-45 in vitro].
Lin T; Yu J; Wei ZG; Hu YF; Wang YN; Li GX
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1066-8. PubMed ID: 21690071
[TBL] [Abstract][Full Text] [Related]
19. Covalently mucoadhesive amphiphilic prodrug of 5-fluorouracil for enhanced permeation and improved oral absorption.
Liu Y; Zhao D; Sun M; Wei W; Wang Y; Zhou J; Zhang R; Wang J; Zhang H; He Z; Kan Q; Sun J
Drug Deliv Transl Res; 2018 Jun; 8(3):645-656. PubMed ID: 29532356
[TBL] [Abstract][Full Text] [Related]
20. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
